Anastrozole vs HMG
FDA Approved vs Extensively Studied
synergistic Mechanism-based · 70% HMG helps manage estrogen conversion from Anastrozole. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
Anastrozole HMG
Weight 293.37 Da —
Half-life ~40-50 hours ~32 hours (FSH component: 39-54 hours)
Type Nonsteroidal aromatase inhibitor (triazole derivative) Gonadotropin mixture
Key Benefits
Anastrozole
01 Potent reduction of circulating estradiol levels (70-80% at standard dose)
02 Prevents gynecomastia during testosterone or anabolic steroid cycles
03 Reduces estrogen-driven water retention and bloating
04 Helps control estrogen-related blood pressure elevation
05 Oral dosing with long half-life allows flexible scheduling (EOD or E3D)
06 Reversible inhibition allows estrogen recovery after discontinuation
07 Well-characterized pharmacokinetics with decades of clinical data
HMG
01 FDA-approved for fertility treatment
02 Stimulates ovarian follicle development
03 Contains both FSH and LH naturally
04 Promotes spermatogenesis in men
05 Cost-effective alternative to recombinant FSH
06 LH activity may improve fertilization rates
07 Long clinical track record
08 Lower OHSS incidence with HP-hMG
Dosing Protocols
Anastrozole
0.25-0.5mg EOD or E3D (estrogen management) / Every other day to every 3 days (cycle support); daily (breast cancer)
HMG
75-150 IU for ovulation induction; 150-300 IU for IVF / Daily during stimulation phase (7-12 days)
Ovulation induction 75-150 IU Daily
IVF stimulation 150-300 IU Daily for 7-12 days
Male fertility 75-150 IU 2-3x weekly
Side Effects
Anastrozole
Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication)
Hot flashes or flushing
Fatigue and general malaise
Mood changes (flat affect, irritability, or low mood)
Decreased libido (when estrogen is suppressed too aggressively)
Headache
HMG
Injection site reactions
Abdominal discomfort
Ovarian enlargement
Mood changes
Headache
Contraindications
Known hypersensitivity to anastrozole or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with tamoxifen or estrogen-containing therapies
Primary ovarian failure
Uncontrolled thyroid or adrenal dysfunction
Sex hormone-dependent tumors
Abnormal uterine bleeding of unknown cause
Ovarian cysts (not due to PCOS)
Pregnancy
Research Evidence
Anastrozole HMG
Status FDA Approved Extensively Studied
References 5 studies 4 studies
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.